预测阿尔茨海默病的长期进展,使用多模式深度学习模型,结合相互作用效应
Yifan Wang1,2, Ruitian Gao1,2, Ting Wei1,2
1Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road, Minhang District, Shanghai, 200240, China.
Journal of translational medicine
|March 12, 2024
概括
一种新的深度学习模型准确地预测了轻度认知障碍 (MCI) 患者的阿尔茨海默病进展情况. 这一进步为患有阿尔茨海默病 (AD) 风险的患者提供了更好的早期干预机会.
科学领域:
- 神经科学和人工智能 人工智能
- 生物医学数据科学 生物医学数据科学
- 医学成像分析 医学成像分析
背景情况:
- 早期识别轻度认知障碍 (MCI) 患有阿尔茨海默病 (AD) 进展高风险的患者对于及时干预至关重要.
- 在临床实践中,准确和长期预测MCI转化为AD仍然是一个重大挑战.
- 开发先进的预测模型对于改善患者护理和神经退行性疾病的结果至关重要.
研究的目的:
- 开发一个可解释的深度学习模型,用于准确和长期预测MCI到AD的进展.
- 通过结合相互作用效应和多模式来提高预测准确度和扩展预测视野.
- 为MCI患者提供一种可以帮助早期诊断和干预策略的工具.
主要方法:
- 一项回顾性研究利用结构磁共振成像 (sMRI),临床评估和阿尔茨海默病神经成像计划 (ADNI) 数据库中的252名MCI患者的遗传数据.
- 开发和交叉验证一种新型深度学习模型,该模型包含跨ADNI-1,ADNI-2/GO和ADNI-3队列的交互效应和多式联络数据.
- 使用诸如AUC (接收器操作特征曲线下的面积),准确度,灵敏度,特异性和F1分数等指标进行性能评估.
主要成果:
- 深度学习模型在4年内实现了MCI转化为AD的优异预测,在交叉验证集上AUC为0.962和准确率为92.92%.
- 在独立测试组中观察到一致的性能,AUC为0.939和准确率为92.86%.
- 结合相互作用效应和多模式数据显著提高了预测准确度 (分别为4.76%和4.29%,P <0.05),证明了对中心间和扫描仪间变量的稳定性.
结论:
- 开发的可解释深度学习模型通过结合交互效应和多模式来增强MCI到AD进展预测,提供了一种新的方法.
- 该模型的卓越准确性和扩展的预测视界对改善痴呆前期患者护理具有重大前景.
- 可量化的生物标志物贡献提供了可解释性,促进了临床信任和在管理轻度认知障碍患者中的应用.
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188


